IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Examiner: Skelding, Zachary S.
	)
Phillip Monk, et al.	) Art Unit: 1644
	)
Application Serial No. 10/564,647	) Confirmation No. 1467
	)
Filed: July 19, 2006	) Attorney's Docket No. 43518-0001 PC US
	)
For: Human Antibody Molecules for IL-13	) **Customer No. 25213**
	)
	)

EXPRESS MAIL: EV 766 021 212 US
DATE MAILED: June 22, 2007

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under *37 C.F.R. §1.97*, subsection (b) because (check all that apply):

    ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
        -- OR --
    ☐ (2) It is being filed within 3 months of entry of a national stage
        -- OR --
    ☒ (3) It is being filed before the mail date of the first Office Action on the merits
        -- OR --

☐   (4)   It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ *37 C.F.R. §1.97(c)*. If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

    ☐   a certification as specified in §1.97(e) is provided below; **or**

    ☐   a fee of $180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ *37 C.F.R. §1.97(d)*. If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

    A.   a certification as specified in §1.97(e) is completed below; and

    B.   a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

    C.   a fee of $130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization*. The Commissioner is hereby authorized to charge the above-referenced fees of **$0.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 43518-0001 PC).

Respectfully submitted,

HELLER EHRMAN LLP

Dated: June 22, 2007   By: _____

                                        Lesile A. Mooi, Reg. No. 37,047

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 43518-0001 PC	SERIAL NO. 10/564,647
	APPLICANT Phillip Monk et al.	
	FILING DATE July 19, 2006	GROUP: 1644

(JUN 2 2 2007 — PATENT & TRADEMARK OFFICE stamp)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO. / PUBLICATION NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,959,085	09/28/1999	Garrone et al.	530	387.3	11/21/1994
	2003-0235555	12/25/2003	Shealey et al.	424	85.1	04/07/2003
	6,811,780	11/02/2004	Furfine et al.	424	145.1	05/01/2003
	2004-0234499	11/25/2004	Shealey et al.	424	85.1	02/27/2004
	2005-0065327	03/24/2005	Monk et al.	530	388.23	07/15/2004

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/36103	06/22/2000	PCT	C12N	15/12	☐	☐
	WO 00/64944	11/02/2000	PCT	C07K	14/715	☐	☐
	WO 00/66631	11/09/2000	PCT	C07K	16/22	☐	☐
	WO 05/062967	07/14/2005	PCT	--	--	☐	☐
	WO 06/003407	01/12/2006	PCT	C07K	16/00	☐	☐
	WO 06/055638	05/26/2006	PCT	C07K	16/24	☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Combined Search and Examination Report Under Sections 17 and 18(3), The UK Patent Office, Patents Act 1977, 4 pages (2004)
	Grunig et al., "Requirement for IL-13 independently of IL-4 in experimental asthma," Science, Vol. 282, pps. 2261-2263 (1998)
	Huang et al., "IL-13 Expression at the sites of allergen challenge in patients with asthma," Journal of Immunology, Vol. 155, pps. 2688-2694 (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 43518-0001 PC		SERIAL NO. 10/564,647
	APPLICANT Phillip Monk et al.		
	FILING DATE July 19, 2006		GROUP: 1644

	Minty et al., "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses," Nature, Vol. 362, pp. 248-250 (1993)	
	Punnonen et al., "The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD3+ T cells," Journal of Allergy and Clinical Immunology, Vol. 100, No. 6, Part 1, pps. 792-801 (1997)	
	Robinson et al., "Predominant T_{H2}-like bronchoalveolar T-lymphocyte population in atopic asthma," The New England Journal of Medicine, Vol. 326, No. 5, pps. 298-304 (1992)	
	Stahl et al., "Cytokine Traps: Heteromeric receptor based protein therapeutics that function as high affinity blockers of cytokine action," FASEB Journal, Vol. 13, No. 7, A1585, (1999)	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SV 2284944 v1
6/22/07 1:37 PM (43518.0001)